Exploration of individuality in drug metabolism by high-throughput metabolomics: The fast line for personalized medicine

Drug Discovery Today

Volumn 21, Issue 1, 2016, Pages 103-110

  Trifonova, Oxana ^a   Knight, Richard A ^b   Lisitsa, Andrey ^a   Melino, Gerry ^b   Antonov, Alexey V ^b  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLISM; GENETIC SCREENING; HIGH THROUGHPUT METABOLOMICS; HIGH THROUGHPUT SCREENING; HUMAN; INDIVIDUALITY; METABOLOMICS; PERSONALIZED MEDICINE; REVIEW; METABOLISM; PROCEDURES;

BIOLOGICAL MARKER; DRUG;

BIOMARKERS; HUMANS; INDIVIDUALITY; METABOLOMICS; PHARMACEUTICAL PREPARATIONS; PRECISION MEDICINE;

EID: 84960303719     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.07.011     Document Type: Review

References (41)

1. M.A. Hamburg, and F.S. Collins The path to personalized medicine N. Engl. J. Med. 363 2010 301 304
2. D.A. Fryburg, and et al. Systems diagnostics: anticipating the next generation of diagnostic tests based on mechanistic insight into disease Drug Discov. Today 19 2014 108 112
3. W.W. Soon, and et al. High-throughput sequencing for biology and medicine Mol. Syst. Biol. 9 2013 640
4. K.S. Frese, and et al. Next-generation sequencing: from understanding biology to personalized medicine Biology (Basel) 2 2013 378 398
5. B.K. Park, and et al. Metabolic activation in drug allergies Toxicology 158 2001 11 23
6. I. Johansson, and M. Ingelman-Sundberg Genetic polymorphism and toxicology - with emphasis on cytochrome p450 Toxicol. Sci. 120 2011 1 13
7. A. Alfirevic, and M. Pirmohamed Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future Pharmacogenomics 11 2010 497 499
8. R.L. Schilsky Personalized medicine in oncology: the future is now Nat. Rev. Drug Discov. 9 2010 363 366
9. L. Madlensky, and et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes Clin. Pharmacol. Ther. 89 2011 718 725
10. E. Cecchin, and et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan J. Clin. Oncol. 27 2009 2457 2465
11. S. Chen, and et al. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11) Proc. Natl. Acad. Sci. U. S. A. 110 2013 19143 19148
12. A. Rostami-Hodjegan, and G.T. Tucker Simulation and prediction of in vivo drug metabolism in human populations from in vitro data Nat. Rev. Drug Discov. 6 2007 140 148
13. A. Sjoerdsma, and et al. Studies on the metabolism and mechanism of action of methyldopa Circulation 28 1963 492 502
14. S. Qiao, and et al. Identification of urinary metabolites of imperatorin with a single run on an LC/Triple TOF system based on multiple mass defect filter data acquisition and multiple data mining techniques Anal. Bioanal. Chem. 405 2013 6721 6738
15. M.R. Anari, and et al. Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir Anal. Chem. 76 2004 823 832
16. J. Han, and et al. Towards high-throughput metabolomics using ultrahigh-field Fourier transform ion cyclotron resonance mass spectrometry Metabolomics 4 2008 128 140
17. T. Fuhrer, and et al. High-throughput, accurate mass metabolome profiling of cellular extracts by flow injection-time-of-flight mass spectrometry Anal. Chem. 83 2011 7074 7080
18. C.E. Parker, and et al. Mass spectrometry in high-throughput clinical biomarker assays: multiple reaction monitoring Top. Curr. Chem. 336 2014 117 137
19. B. Wen, and M. Zhu Applications of mass spectrometry in drug metabolism: 50 years of progress Drug Metab. Rev. 47 2015 71 87
20. O. Trifonova, and et al. Postgenomics diagnostics: metabolomics approaches to human blood profiling OMICS 17 2013 550 559
21. R. Kirk Targeted therapies: the toxic reality of new drugs Nat. Rev. Clin. Oncol. 9 2012 488
22. R.J. Weber, and et al. Characterization of isotopic abundance measurements in high resolution FT-ICR and Orbitrap mass spectra for improved confidence of metabolite identification Anal. Chem. 83 2011 3737 3743
23. G. Madalinski, and et al. Direct introduction of biological samples into a LTQ-Orbitrap hybrid mass spectrometer as a tool for fast metabolome analysis Anal. Chem. 80 2008 3291 3303
24. M. Baker Metabolomics: from small molecules to big ideas Nat. Methods 8 2011 117 121
25. J. Han, and et al. Mass spectrometry-based technologies for high-throughput metabolomics Bioanalysis 1 2009 1665 1684
26. J. Han, and et al. Metabolic profiling of bile acids in human and mouse blood by LC-MS/MS in combination with phospholipid-depletion solid-phase extraction Anal. Chem. 87 2015 1127 1136
27. M. Kanehisa, and S. Goto KEGG: Kyoto encyclopedia of genes and genomes Nucleic Acids Res. 28 2000 27 30
28. A.V. Antonov, and et al. TICL - a web tool for network-based interpretation of compound lists inferred by high-throughput metabolomics FEBS J. 276 2009 2084 2094
29. C. Papan, and et al. Systematic screening for novel lipids by shotgun lipidomics Anal. Chem. 86 2014 2703 2710
30. R. Breitling, and et al. Ab initio prediction of metabolic networks using Fourier transform mass spectrometry data Metabolomics 2 2006 155 164
31. H. Zhang, and et al. Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection Rapid Commun. Mass Spectrom. 22 2008 2082 2088
32. H. Zhang, and et al. Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry J. Mass Spectrom. 44 2009 999 1016
33. W.A. Korfmacher Principles and applications of LC-MS in new drug discovery Drug Discov. Today 10 2005 1357 1367
34. T. Fuhrer, and N. Zamboni High-throughput discovery metabolomics Curr. Opin. Biotechnol. 31C 2015 73 78
35. E.R. Kisanga, and et al. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial Clin. Cancer Res. 10 2004 2336 2343
36. L. Gallicchio, and et al. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer Breast Cancer Res. Treat. 85 2004 89 97
37. F. Innocenti, and et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J. Clin. Oncol. 22 2004 1382 1388
38. E. Coezy, and et al. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth Cancer Res. 42 1982 317 323
39. V.C. Jordan Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance Breast Cancer Res. Treat. 2 1982 123 138
40. I. Amelio, and et al. DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information Cell Death Dis. 5 2014 e1051
41. R.A. Knight, and et al. Large scale integration of drug-target information reveals poly-pharmacological drug action mechanisms in tumor cell line growth inhibition assays Oncotarget 5 2014 659 666